In vivo comparison of copper blood-pool agents: Potential radiopharmaceuticals for use with copper-62

C. J. Mathias, M. J. Welch, M. A. Green, H. Diril, C. F. Meares, R. J. Gropler, S. R. Bergmann

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Two techniques for labeling of albumin with copper-67 (67Cu) and 62Cu were investigated; one using the native Cu(II) binding site of the protein and the other employing a bifunctional chelate, 6-bromoacetamidobenzyl-1,4,8,11-tetraazacyclotetradecane-N,N'N'', N'''-tetraac etic acid (Br-benzyl-TETA or BAT), conjugated to the protein. Rat biodistribution experiments with 67Cu demonstrated retention of i.v. 67Cu-benzyl-TETA-albumin in the blood pool identical to co-injected 125I-albumin. By contrast, i.v. administration of either [67Cu]-Cu-acetate or [67Cu]-Cu-acetate pre-mixed with albumin results in relatively rapid clearance of blood-pool radioactivity as the tracer is excreted into the urine. The 62Cu-benzyl-TETA-albumin radiopharmaceutical was obtained in ca. 17% radiochemical yield (end of synthesis, without decay correction) following a procedure that can be completed in 15-18 min. In PET experiments with a baboon, myocardial blood volume images with 62Cu-benzyl-TETA-albumin were identical to those obtained with C15O. Use of the 62Cu-benzyl-TETA-albumin image for blood-pool subtraction of a 62Cu-PTSM myocardial perfusion image is illustrated. Copper-62-benzyl-TETA-HSA should be a useful, generator-produced radiotracer for the detection of the vascular pool at PET facilities without cyclotrons.

Original languageEnglish (US)
Pages (from-to)475-480
Number of pages6
JournalJournal of Nuclear Medicine
Volume32
Issue number3
StatePublished - Jan 1 1991

    Fingerprint

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Mathias, C. J., Welch, M. J., Green, M. A., Diril, H., Meares, C. F., Gropler, R. J., & Bergmann, S. R. (1991). In vivo comparison of copper blood-pool agents: Potential radiopharmaceuticals for use with copper-62. Journal of Nuclear Medicine, 32(3), 475-480.